Publications

5808 Results

Long-term effect estimation when combining clinical trial and observational follow-up datasets

Authors
Cheng G
Journal / Conference
J Amer Stat Assoc. 2025 Jul 15:1-10; publ online: 27 Aug 2025; doi: 10.1080/01621459.2025.2526703
Year
2025
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratification – an NCI myeloMATCH and SWOG report

Authors
Min Fang, MD, PhD
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL). #3501 poster. Blood (2025) 146 (Supplement 1): 3501
Year
2025
Research Committee(s)
Leukemia
Study Number(s)
MYELOMATCH

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) vs. venetoclax and rituximab (VR) in previously untreated Waldenstro¨m’s macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL)

Authors
Sikander Ailawadhi, MD
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL). #1840 TIPs poster. Blood (2025) 146 (Supplement 1): 1840
Year
2025
Research Committee(s)
Myeloma
Study Number(s)
S2005

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myeloMATCH substudy (MM1OA-S03)

Authors
Eric Huselton, MD
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL). 3466 poster TIPs. Blood (2025) 146 (Supplement 1): 3466
Year
2025
Research Committee(s)
Leukemia
Study Number(s)
MM1OA-S03

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study

Authors
Nancy Bartlett, MD
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL), 2025. Abstract 1851 poster. Blood (2025) 146 (Supplement 1): 1851
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE): Cluster Randomized Controlled Trial of Decision Support for Breast Cancer Chemoprevention, SWOG 1904

Authors
Katherine D. Crew
Journal / Conference
San Antonio Breast Cancer Symposium (December 9-12, 2025, San Antonio, TX)
Year
2025
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S1904

Sentinel Lymph Node Biopsy and Clinical Outcome of Patients with Node-Positive Breast Cancer in the RxPONDER Trial (S1007)

Authors
Rosa F. Hwang
Journal / Conference
San Antonio Breast Cancer Symposium (December 9-12, 2025, San Antonio, TX)
Year
2025
Research Committee(s)
Breast
Study Number(s)
S1007

Sex differences in chemotherapy completion and adverse events among patients with colon cancer (CALGB/SWOG 80702) (Alliance)

Authors
E. Cheng
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #3624 poster
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance)

Authors
S.K. Char
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #LBA3509
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Pragmatica-Lung (SWOG S2302): A prospective pragmatic randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer

Authors
K.H. Dragnev
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #LBA8671
Year
2025
Research Committee(s)
Lung
Study Number(s)
S2302